The Radical Scavenger IAC (bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) decantionate) Decreases Mortality, Enhances Cognitive Functions in Water Maze and Reduces Amyloid Plaque Burden in hAβPP Transgenic Mice
Affiliations: [a] Cerebricon Limited, Kuopio, Finland | [b] Medestea Research, Turin, Italy | [c] Department of Biotechnology and Molecular Medicine, University of Eastern Finland, Kuopio, Finland | [d] Departments of Pharmacology and Biology, Alma Mater Studiorum, Bologna, Italy
Correspondence:
[*]
Correspondence to: Enzo Spisni, Department of Pharmacology and Biology, Alma Mater Studiorum, Via Selmi 3, 40126 Bologna, Italy. Fax: +39 051 209 42 86; E-mail: [email protected].
Abstract: The purpose of this study was to evaluate the efficacy of the radical scavenger IAC (bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) decantionate) in alleviating behavioral deficits and reducing amyloid-β (Aβ) accumulation in an Alzheimer's disease (AD) transgenic Tg2576 mouse model. Daily treatment with IAC (3–30 mg/kg, i.p.) was started at the age of 6 months and continued until the mice were 13 months old. At the age of 9 months and again at 12 months, the mice were tested in open field and water maze tests. At the age of 13 months, the mice were sacrificed and the brains processed for immunohistochemistry. Mortality was significantly reduced in all IAC-treated groups. In addition, IAC treatment improved the water maze hidden platform training performance but had no effect on motor activity in the open field or water maze swim speed in transgenic mice. Lastly, IAC treatment (10 mg/kg) significantly reduced the cortical Aβ plaque burden. In vitro, IAC is able to increase the number of neurites and neurite branches in cultured cortical primary neurons. In conclusion, IAC slowed down the development of the AD-like phenotype in Tg2576 mice and accelerated neurite growth in cultured neurons.
